Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 724 of 5804
-
Experimental gene therapy targets Tay-Sachs and sandhoff in kids
Disease control TerminatedThe AXO-GM2-001 study is an open-label, two-stage clinical trial designed to evaluate safety and dose-escalation (Stage 1) and safety and efficacy (Stage 2) of a bilateral thalamic and intracisternal/intrathecal infusion of AXO-AAV-GM2 in pediatric participants with GM2 Gangliosi…
Phase: PHASE1 • Sponsor: Terence Flotte • Aim: Disease control
Last updated Jun 26, 2026 13:03 UTC
-
Scientists hunt for pancreatic cancer signs in waste fluid
Diagnosis Recruiting nowPancreatic ductal adenocarcinoma (PDAC) remains among cancers with a very poor prognosis (1-year survival \<20%). Endoscopic ultrasound with fine needle aspiration (EUS/FNA) is the common examination for all patients with suspicious pancreatic mass. A method was recently develope…
Sponsor: University Hospital, Montpellier • Aim: Diagnosis
Last updated Jun 27, 2026 14:01 UTC
-
Blood test could cut lung cancer diagnosis time
Diagnosis OngoingThis study will assess the utility of liquid biopsy to accelerate the time to treatment for patients with newly diagnosed advanced non-small cell lung cancer, compared to the conventional diagnostic pathway of molecular testing of tumour tissue after imaging and biopsy.
Sponsor: University Health Network, Toronto • Aim: Diagnosis
Last updated Jun 27, 2026 08:05 UTC
-
Groundbreaking trial could spare thousands of breast cancer patients from unnecessary surgery
Disease control OngoingCurrently, axillary surgery for breast cancer is considered as staging procedure that does not seem to influence breast cancer mortality, since the risk of developing metastasis depends mainly on the biological behaviour of the primary (seed-and-soil model). Based on this, the po…
Phase: NA • Sponsor: Toralf Reimer, MD PhD • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug shows promise in advanced bladder cancer battle
Disease control CompletedThe primary objective of this study is to assess overall survival (OS) with sacituzumab govitecan-hziy in comparison with treatment of physician's choice (TPC) in participants with metastatic or locally advanced unresectable urothelial cancer (UC).
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy aims to stop lung cancer return after surgery
Disease control OngoingThis is an open-label, randomised, two-arm, phase III, multi-centre clinical trial. 210 stage IB-IIIA, completely resected, non-small cell lung cancer patients will be enrolled in this trial to evaluate the disease free survival between experimental arm (Adjuvant Chemotherapy-Im…
Phase: PHASE3 • Sponsor: Fundación GECP • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo therapy offers hope for frail lung cancer patients
Disease control OngoingThis phase II trial studies the side effects of radiation therapy followed by atezolizumab in treating patients with stage II or III non-small cell lung cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kil…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Immunotherapy combo shows promise in Tough-to-Treat anal cancer
Disease control CompletedThis study is a Phase 3 global, multicenter, placebo-controlled double-blind randomized study that will enroll participants with inoperable locally recurrent or metastatic SCAC not previously treated with systemic chemotherapy.
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Could a 'smart' stem cell transplant free patients from a lifetime of anti-rejection drugs?
Disease control Recruiting nowThis research study is evaluating the safety and efficacy of the IS-free Treg-cell graft-engineered haplo transplant method in people with relapsed/refractory and Ultra-high risk acute myeloid leukemia (AML) and/or myelodysplastic syndromes (MDS) receiving a haploidentical donor …
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Could a tiny neck implant calm rheumatoid arthritis without pills?
Disease control OngoingThe RESET-RA study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderate to severe rheumatoid arthritis who have had an inadequate response or intolerance to biologic or targeted synthetic Disease-Modif…
Phase: PHASE3 • Sponsor: SetPoint Medical Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug combo shows promise for Hard-to-Treat HER2 cancers
Disease control OngoingThis trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial have either spread to other parts of the body (metastatic) or cannot be removed completely with…
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New combo targets tough pancreatic tumors
Disease control Recruiting nowThis phase I/II trial studies the safety, side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced). M3814 may stop the…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Could a double-dose flu vaccine protect vulnerable transplant patients better?
⭐️ VACCINE ⭐️ OngoingThe influenza virus is a significant cause of morbidity in adult solid organ transplant (SOT) recipients. However, these individuals show a suboptimal response to vaccines including the standard-dose (SD) inactivated influenza vaccine (IIV). Recent studies have investigated two s…
Phase: PHASE2 • Sponsor: Vanderbilt University Medical Center • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 08:13 UTC
-
New combo shot aims to stop early breast cancer from returning
Disease control OngoingThis research study is studying a combination of HER2-directed therapies (trastuzumab and pertuzumab) and hormonal therapy as a treatment after surgery for hormone receptor positive breast cancer. The study drugs involved in this study are: * A combination of trastuzumab and pe…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Immunotherapy combo shows promise in preventing High-Risk uterine cancer return
Disease control OngoingThe purpose of this study is to compare pembrolizumab + adjuvant chemotherapy with placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to disease-free survival (DFS) as assessed radiographically by the investigator or by histopathologic confirmation of sus…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New hope for stubborn lung infection: bedaquiline combo shows promise
Disease control CompletedThe purpose of the study is to evaluate the efficacy of bedaquiline (BDQ) compared with rifamycin when administered as part of a treatment regimen with clarithromycin (CAM) and ethambutol (EB) in adult participants with treatment-refractory Mycobacterium avium complex-lung diseas…
Phase: PHASE2, PHASE3 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for rare leukemia: drug targets MEK gene in BRAF-Negative patients
Disease control Recruiting nowBackground: Most people with hairy cell leukemia have a BRAF gene mutation. They can be treated with BRAF inhibitors, drugs that target this mutation. For people who do not have this mutation, BRAF inhibitors are not a treatment option. We found that in hairy cell leukemia, when…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Mobile CT vans aim to detect lung cancer in smokers as young as 40
Diagnosis Recruiting nowLow-dose CT Screening has been shown in two large trials in the United States (NLST) and Europe (NELSON) to increase overall survival in subjects 55 years of age and older with a strong smoking history. Unfortunately, in both North Carolina (NC) and South Carolina (SC), subjects …
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Diagnosis
Last updated Jul 15, 2026 00:00 UTC
-
Could adding radiation to immunotherapy keep lung cancer at bay?
Disease control Recruiting nowThis phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of small cell lung cancer that has spread ou…
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat sarcomas
Disease control OngoingThe hypothesis of this study is that the response rate of soft tissue sarcoma will be improved with the addition of PD-1 and CTLA-4 inhibition to cabozantinib, and that cabozantinib priming will increase the response to nivolumab and ipilimumab.
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC